Differential pattern of brain-specific CSF proteins tau and amyloid-β in Parkinsonian syndromes

Mov Disord. 2010 Jul 15;25(9):1284-8. doi: 10.1002/mds.22895.


To evaluate cerebrospinal fluid (CSF) proteins reflecting processes of neurodegeneration and glial activation in progressive supranuclear palsy (PSP; Richardson's syndrome, n = 20; PSP-Parkinsonism, n = 7) and multiple system atrophy (MSA, n = 25), we analyzed tau, phosphorylated tau, amyloid-beta(1-42) (Abeta1-42), Abeta1-40, glial fibrillary acidic protein (GFAP), and CSF routine variables. Individuals with PSP-Parkinsonism and MSA had elevated tau levels when compared with Richardson's syndrome, Parkinson's disease (PD), and age-matched controls (P <or= 0.001). Ratios of P-tau/T-tau were significantly different in Parkinsonian syndromes. CSF Abeta1-42 was decreased only in patients with Richardson's syndrome. In a subset of Parkinsonian syndromes, we found elevated GFAP concentrations and increased CSF/serum albumin ratios. There were no correlations between biomarker concentrations and clinical scores in any of the diseases. In conclusion, this preliminary data show that changes in CSF tau and Abeta1-42 may indicate different protein processing in PSP patients and might, therefore, be relevant in the differentiation of PSP subtypes.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Amyloid beta-Peptides / cerebrospinal fluid*
  • Female
  • Glial Fibrillary Acidic Protein / cerebrospinal fluid
  • Humans
  • Male
  • Middle Aged
  • Parkinsonian Disorders / cerebrospinal fluid*
  • Peptide Fragments / cerebrospinal fluid*
  • Statistics, Nonparametric
  • tau Proteins / cerebrospinal fluid*


  • Amyloid beta-Peptides
  • Glial Fibrillary Acidic Protein
  • Peptide Fragments
  • amyloid beta-protein (1-42)
  • tau Proteins